Table 1 The character and baseline of 7 RCTs
From: Omadacycline for treatment of acute bacterial infections: a meta-analysis of phase II/III trials
Study, year published | Study duration | Study site | Study population | No of population (n) | Dose regimen | |||
|---|---|---|---|---|---|---|---|---|
Omadacycline | Comparators | Omadacycline | Comparators | |||||
Noel, et al. 2012 | July 2007 and January 2008 | 11 sites in USA | ≥ 18 years and cSSSI | 118 | 116 | 100 mg q24 h | linezolid 600 mg iv q12h. | |
O’Riordan, et al. 2019 (OASIS-1) | June 2015 and May 2016 | 55 sites in 14 countries | ≥ 18 years and ABSSSI | 323 | 322 | 100 mg iv q12h/100 mg iv q24h or 300 mg po q24h | linezolid 600 mg iv/po q12h | |
Stets, et al. 2019 | November 2015 and February 2017 | 86 sites in 26 countries | ≥ 18 years and CABP | 386 | 388 | 100 mg iv q12h/100 mg iv q24h or 300 mg po q24h | moxifloxacin 400 mg iv/po q24h | |
O’Riordan, et al. 2019 (OASIS-2) | Aug 2016and June 2017 | 33 sites in USA | ≥ 18 years and SSSI | 368 | 367 | 450 mg po q24h and 300 mg po q24h | linezolid 600 mg po bid | |
NCT00865280 | April 2009 and April 2010 | USA | ≥ 18 years and cSSSI | 70 | 73 | 100 mg iv q24h and 300 mg po q24h. | linezolid 600 mg iv/po q12h plus moxifloxacin 400 mg q24h iv/po | |
NCT03425396 | January 2018 and June 2019 | USA | ≥ 18 years and cystitis | 171 | 54 | 300 mg po q12h/ q24h 450 mg po q12h/300 mg po q24h 450 mg po q12h/q24h 450 mg q12h | nitrofurantoin 100 mg po q12h | |
NCT03757234 | November 2018 and July 2019 | 5 countries | 18–65 years and acute pyelonephritis | 127 | 74 | 200 mg iv q24h 200 mg/100 mg iv q24h 200 mg iv/300 mg po or 100 iv q24h 200 mg iv/450 mg po or 100 mg iv q24h | levofloxacin 750 mg po/iv | |